Exclusive: Pfizer to launch consumer health sale in November - sources
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
BofA/Merrill Lynch Downgrades GlaxoSmithKline (GSK) to Neutral
October 26, 2017 4:42 AM EDTBofA/Merrill Lynch downgraded GlaxoSmithKline (NYSE: GSK) from Buy to Neutral.
Analyst Graham Parry says the valuation is not demanding and sees growing uncertainties likely capping P/E recovery into 2018 stemming from margin pressure and consensus EPS reductions on Advair generics... More



